SEC Company Response from VYNE Therapeutics Inc. (VYNE) (CIK 0001566044) (VYNE) — May 11, 2021
VYNE Therapeutics Inc. (VYNE) (CIK 0001566044)
Date: May 11, 2021 · CIK: 0001566044 · Accession: 0001104659-21-064533
AI Filing Summary & Sentiment
File numbers found in text: 333-255841
Letter
VYNE Therapeutics Inc.
520 U.S. Highway 22, Suite 204
Bridgewater, New Jersey 08807
May 11, 2021
VIA EDGAR AND EMAIL
Securities and Exchange Commission
Division of Corporation Finance
100 F Street NE
Washington, D.C. 20549
Re: VYNE Therapeutics Inc.
Request for Acceleration
Registration Statement on Form S-3
Filed May 6, 2021
File No. 333-255841 (the “Registration Statement”)
Ladies and Gentlemen:
In accordance with Rules 460 and 461 under the Securities Act of 1933, as amended (the “Securities Act”), VYNE Therapeutics Inc., a Delaware corporation (the “Company”), respectfully requests that the effective date of the above-referenced Registration Statement be accelerated by the Securities and Exchange Commission (the “Commission”) so that the Registration Statement, as then amended, will become effective under the Securities Act at 4:00 p.m., New York City time, on Friday, May 14, 2021 or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.
The Company requests that it be notified of such effectiveness by a telephone call to Andrea L. Nicolas, Esq. of Skadden, Arps, Slate, Meagher & Flom LLP, the Company’s counsel, at (212) 735-3416, and that such effectiveness also be confirmed in writing.
[Signature Page Follows]
Very truly yours,
VYNE Therapeutics Inc.
Show Raw Text
CORRESP
1
filename1.htm
VYNE Therapeutics Inc.
520 U.S. Highway 22, Suite 204
Bridgewater, New Jersey 08807
May 11, 2021
VIA EDGAR AND EMAIL
Securities and Exchange Commission
Division of Corporation Finance
100 F Street NE
Washington, D.C. 20549
Re:
VYNE Therapeutics Inc.
Request for Acceleration
Registration Statement on Form
S-3
Filed May 6, 2021
File No. 333-255841 (the “Registration
Statement”)
Ladies and Gentlemen:
In accordance with Rules 460 and 461 under the
Securities Act of 1933, as amended (the “Securities Act”), VYNE Therapeutics Inc., a Delaware corporation (the “Company”),
respectfully requests that the effective date of the above-referenced Registration Statement be accelerated by the Securities and Exchange
Commission (the “Commission”) so that the Registration Statement, as then amended, will become effective under the
Securities Act at 4:00 p.m., New York City time, on Friday, May 14, 2021 or at such later time as the Company or its counsel may orally
request via telephone call to the staff of the Division of Corporation Finance of the Commission.
The Company requests that it be notified of such
effectiveness by a telephone call to Andrea L. Nicolas, Esq. of Skadden, Arps, Slate, Meagher & Flom LLP, the Company’s counsel,
at (212) 735-3416, and that such effectiveness also be confirmed in writing.
[Signature Page Follows]
Very truly yours,
VYNE Therapeutics Inc.
By:
/s/ David Domzalski
Name:
David Domzalski
Title:
Chief Executive Officer
cc: Andrea L. Nicolas, Esq.
Skadden, Arps, Slate, Meagher & Flom
LLP
[Signature Page to Acceleration Request]